Following strong Q1 orders and earnings, we have raised our 2024–2026e clean EPS by 4% on average and our target price to EUR20 (18). We reiterate our BUY. We continue to forecast multiyear sales and earnings growth for Wärtsilä, and view it as attractively valued (see our recent report ‘Refuelled engines’).
Schibsted delivered a weak Q1 report, including figures below expectations adjusted for News Media due to higher costs YOY and the withdrawal of the 2024 guidance for Nordic Marketplaces. We reiterate our HOLD and NOK320 target price, with negative estimate revisions offset by peer group multiples expansion.
While the Q1 results disappointed the market, we consider a ~USD70m–120m EBITDA miss to be within a normal standard deviation and have made only minor estimate changes. Yara’s share price in dollar terms (USD29) is among its lowest since 2010, yet consensus earnings forecasts are at normalised levels. We believe this reflects investor fears it will act irrationally with its capex (NIBD/EBITDA of 2.3x does not give it the muscle to carry out the announced blue ammonia investments). While we hear ...
Recycling reported disappointing Q1 adj. EBITA of NOK7m on lower revenues, which also hurt margins. Given the solid order intake – a bright spot in the report – we have only reduced our 2025–2026e EPS by 3–4%. We struggle to justify the 2024e P/E of 39x (similar to the ‘Magnificent 7’, with ~20% average annual growth rates) coupled with 2024e revenue growth of only ~3–4% and risk to 2025–2026e growth from potential delays in Poland and the UK’s DRS implementations. We reiterate our SELL and NOK9...
Despite weaker organic growth than we had expected, Q1 had strong cost control and solid margins. We have raised our 2024–2026e adj. EBIT by c1% on average, having become more positive on margins. We reiterate our HOLD and SEK140 target price, continuing to see risk/reward as fairly balanced.
The market is pricing Safe Bulkers at a ~50% discount to NAV, which we believe mitigates any potential vessel value risk and leaves a still-favourable risk/reward towards the dry bulk supply-side narrative. However, we find the recent dry bulk freight market strength counter to fundamental demand drivers in China (importer of ~75% of seaborne iron ore volumes and ~50% of overall volumes), and see some market downside risk near-term. Still, at today’s share price, we see an attractive 17% earning...
Kambi showed steps in the right direction in Q1 after expectations were re-based in conjunction with the Q4 report. We have raised our 2024e EBIT by 5% following the earnings beat in Q1, and find the implicit EBIT guidance of EUR~15m fairly conservative in light of e.g. the upcoming onboarding of Svenska Spel in Sweden and LiveScore in the UK. We reiterate our BUY and have raised our target price to SEK190 (180).
Kambi showed steps in the right direction in Q1 after expectations were re-based in conjunction with the Q4 report. We have raised our 2024e EBIT by 5% following the earnings beat in Q1, and find the implicit EBIT guidance of EUR~15m fairly conservative in light of e.g. the upcoming onboarding of Svenska Spel in Sweden and LiveScore in the UK. We reiterate our BUY and have raised our target price to SEK190 (180).
This week, Equinor, Aker BP and Vår Energi released their Q1 results. In short: Equinor reported on the strong side, with a solid FCF beat fuelled by a working capital tailwind. Aker BP had a solid Q1 all around, while there was limited new news on Johan Sverdrup. For Vår Energi, with the results in line with our expectations, we believe investor focus remains on the Jotun FPSO sail-away.
Disregarding some unclarity on fixed-cost under-absorption during the conference call, we view SKF’s Q1 report as solid, especially the better-than-expected adj. EBIT margin, supporting the longer-term margin story. However, cash flow was on the soft side and we struggle to bridge the 2024 guidance, which could become a more prominent risk later in the year. We have raised our 2024–2026e adj. EBIT by 3% and target price to SEK250 (240), and reiterate our HOLD.
Q1 reporting season kicked off this week, with results from Nyfosa, Entra, Wallenstam, Fabege, KMC Properties, Pandox, and Catena. In other news, Public Property Invest is to be listed on the Oslo stock exchange on 29 April. The weighted-average implied EBITDA yields on the stocks we cover are 4.75% for 2024e and 5.04% for 2025e.
Helped by strong trading income, HELG reported a Q1 ROE of ~12% versus its >11% target, despite the pre-announced elevated loan losses. With one less interest day and margin pressure, ‘real NII’ fell 2.2% QOQ. While down QOQ, the CET1 ratio remained solid at 18.1% (>16.5% target). We have cut our 2025–2026e EPS by ~3–5%, driven by lower NII, and lowered our target price to NOK134 (139). Trading at a 2025e P/E of ~9.0x, we continue to find a more attractive risk/reward elsewhere in the sector and...
We are slightly below consensus on Q1e LCY sales growth (we forecast 19.4%, consensus 21.4%) and LCY operating profit growth (we forecast 16.8%, consensus 19.5%), due to lower expected Wegovy sales. However, we believe the Ozempic US prescription trend will prompt management to raise the 2024 guidance to LCY sales growth of 20–28% (18–26%) and LCY operating profit growth of 23–31% (21–29%). We reiterate our BUY and DKK1,100 target price.
Telia reported Q1 service revenue, EBITDA, and cash flow below consensus. However, with the SEK300m/year service agreement after the sale of the Danish operation, we have made limited revisions to our 2024–2025e service revenue, EBITDA, and cash flow. We reiterate our BUY but have cut our target price to SEK33 (35).
Continued weak end-market demand, lower production volumes, and a legacy-business exit weighed on sales and earnings in Q1. We expect organic growth and earnings to remain under pressure in 2024. Following the Q1 results, we reiterate our SELL and SEK63 target price.
We reiterate our BUY and SEK1,700 target price after healthy but in-line Q1 results (Live revenue growth >25% YOY at constant FX). In our view, the weak share price despite a healthy start to the year, promising new games pipeline, high-conviction growth outlook (growth investments, e.g. recruitment), and long-awaited Live dealer contract with leading operator bet365 offers a solid buying opportunity.
We see this as a decent report, with Q1 adj. EBITDA of USD15m, USD7m above consensus. Underlying adj. EBITDA looks however to be broadly in line with expectations due to accounting changes in Feed Ingredients. The company sees a good market outlook across divisions and we see 2–4% positive revisions to consensus 2024e adj. EBITDA. We expect a slightly positive share price reaction today.
Q1 was mixed, with momentum still improving in Finland and Humana returning to acquisition mode, targeting Team Olivia (TO) Norway. While we find the deal value-enhancing, Humana’s relatively high financial gearing would suggest a deleveraging focus near-term, and the departure of CEO Johanna Rastad has added uncertainty at the wrong time. We reiterate our HOLD, but have raised our target price to SEK30 (27) on higher forecasts.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.